[Therapy with CSE inhibitors--more than lipid lowering?]

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Public Health

Context:

• Elevated plasma cholesterol is a known risk factor for coronary heart disease (CHD).
• Previous interventions (fibrates, nicotinic acid, colestyramine) reduced coronary events but not mortality.
• Statins represent a more potent class of lipid-lowering drugs.

Purpose:

• To evaluate the efficacy of lipid-lowering therapies, particularly statins, in cardiovascular disease prevention.
• To assess the impact of cholesterol reduction on mortality, morbidity, and specific cardiovascular events.
• To explore novel mechanisms underlying the rapid clinical benefits of lipid lowering.

Summary:

• Statins have demonstrated significant reductions in major coronary events and interventions in both primary and secondary prevention trials (e.g., WOSCOPS, 4S).
• These drugs effectively lower CHD-associated and overall mortality, particularly in high-risk populations including women, the elderly, and diabetics.
• Cholesterol lowering also improves angina, prognosis post-heart transplant, and reduces stroke incidence.

Impact:

• Statins have revolutionized cardiovascular disease management by providing substantial risk reduction.
• Evidence supports the use of statins across diverse patient groups and for multiple cardiovascular outcomes.
• Emerging research suggests pleiotropic effects of statins on inflammation, vascular function, and coagulation contribute to clinical benefits.